It is recommended that future research efforts concentrate on ascertaining whether KCNN4‐directed therapies can effectively modulate the immune microenvironment, with the objective of enhancing immune activation and tumor control in pancreatic cancer. The gene discussed is KCNN4; the disease is familial pancreatic carcinoma.